Last reviewed · How we verify
Candesartan plus Hydrochlorothiazide
Candesartan plus Hydrochlorothiazide is a Angiotensin II receptor blocker + Thiazide diuretic combination Small molecule drug developed by Novartis. It is currently in Phase 3 development for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients.
Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.
Candesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients.
At a glance
| Generic name | Candesartan plus Hydrochlorothiazide |
|---|---|
| Sponsor | Novartis |
| Drug class | Angiotensin II receptor blocker + Thiazide diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Candesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, causing vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urine output and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.
Approved indications
- Hypertension (high blood pressure)
- Reduction of cardiovascular events in hypertensive patients
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (elevated potassium)
- Hypokalemia (low potassium)
- Hyperuricemia (elevated uric acid)
- Headache
- Cough
- Hypotension
Key clinical trials
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- The Precision Hypertension Care Study (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy (PHASE4)
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323 (PHASE1)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control (PHASE3)
- Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan plus Hydrochlorothiazide CI brief — competitive landscape report
- Candesartan plus Hydrochlorothiazide updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Candesartan plus Hydrochlorothiazide
What is Candesartan plus Hydrochlorothiazide?
How does Candesartan plus Hydrochlorothiazide work?
What is Candesartan plus Hydrochlorothiazide used for?
Who makes Candesartan plus Hydrochlorothiazide?
What drug class is Candesartan plus Hydrochlorothiazide in?
What development phase is Candesartan plus Hydrochlorothiazide in?
What are the side effects of Candesartan plus Hydrochlorothiazide?
What does Candesartan plus Hydrochlorothiazide target?
Related
- Drug class: All Angiotensin II receptor blocker + Thiazide diuretic combination drugs
- Target: All drugs targeting AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension (high blood pressure)
- Indication: Drugs for Reduction of cardiovascular events in hypertensive patients
- Compare: Candesartan plus Hydrochlorothiazide vs similar drugs
- Pricing: Candesartan plus Hydrochlorothiazide cost, discount & access